Abstract A080: A phase 1 study of single-agent pexidartinib in Asian patients with advanced solid tumors (NCT02734433)
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Trials"
DOI: 10.1158/1535-7163.targ-17-a080
Abstract: Background: Pexidartinib is a novel, orally active, small-molecule kinase inhibitor that selectively targets the colony-stimulating factor-1 receptor (CSF1R), as well as the receptors c-kit and oncogenic Flt3. Based on these targets, pexidartinib may inhibit tumor… read more here.
Keywords: phase; asian patients; pexidartinib; study ... See more keywords